vs

Side-by-side financial comparison of Invivyd, Inc. (IVVD) and OptimizeRx Corp (OPRX). Click either name above to swap in a different company.

OptimizeRx Corp is the larger business by last-quarter revenue ($32.2M vs $17.2M, roughly 1.9× Invivyd, Inc.). OptimizeRx Corp runs the higher net margin — 15.6% vs -64.3%, a 79.9% gap on every dollar of revenue. On growth, Invivyd, Inc. posted the faster year-over-year revenue change (24.5% vs -0.2%).

Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.

OptimizeRx Corp is a U.S.-headquartered digital health technology company that delivers patient engagement, medication affordability and clinical communication solutions to life sciences enterprises, healthcare providers and pharmacy partners. Its core offerings include digital medication savings tools, patient support programs, and therapeutic area-specific resources to boost medication access and treatment adherence.

IVVD vs OPRX — Head-to-Head

Bigger by revenue
OPRX
OPRX
1.9× larger
OPRX
$32.2M
$17.2M
IVVD
Growing faster (revenue YoY)
IVVD
IVVD
+24.7% gap
IVVD
24.5%
-0.2%
OPRX
Higher net margin
OPRX
OPRX
79.9% more per $
OPRX
15.6%
-64.3%
IVVD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IVVD
IVVD
OPRX
OPRX
Revenue
$17.2M
$32.2M
Net Profit
$-11.1M
$5.0M
Gross Margin
74.8%
Operating Margin
-73.0%
26.6%
Net Margin
-64.3%
15.6%
Revenue YoY
24.5%
-0.2%
Net Profit YoY
40.0%
6535.9%
EPS (diluted)
$0.02
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVVD
IVVD
OPRX
OPRX
Q4 25
$17.2M
$32.2M
Q3 25
$13.1M
$26.1M
Q2 25
$11.8M
$29.2M
Q1 25
$11.3M
$21.9M
Q4 24
$13.8M
$32.3M
Q3 24
$9.3M
$21.3M
Q2 24
$2.3M
$18.8M
Q1 24
$0
$19.7M
Net Profit
IVVD
IVVD
OPRX
OPRX
Q4 25
$-11.1M
$5.0M
Q3 25
$-10.5M
$779.0K
Q2 25
$-14.7M
$1.5M
Q1 25
$-16.3M
$-2.2M
Q4 24
$-18.4M
$-78.0K
Q3 24
$-60.7M
$-9.1M
Q2 24
$-47.2M
$-4.0M
Q1 24
$-43.5M
$-6.9M
Gross Margin
IVVD
IVVD
OPRX
OPRX
Q4 25
74.8%
Q3 25
67.2%
Q2 25
63.8%
Q1 25
60.9%
Q4 24
68.1%
Q3 24
63.1%
Q2 24
62.2%
Q1 24
62.0%
Operating Margin
IVVD
IVVD
OPRX
OPRX
Q4 25
-73.0%
26.6%
Q3 25
-84.0%
7.9%
Q2 25
-127.8%
10.9%
Q1 25
-149.7%
-9.6%
Q4 24
-139.1%
11.2%
Q3 24
-670.0%
-40.2%
Q2 24
-2175.2%
-19.9%
Q1 24
-25.5%
Net Margin
IVVD
IVVD
OPRX
OPRX
Q4 25
-64.3%
15.6%
Q3 25
-79.7%
3.0%
Q2 25
-124.4%
5.2%
Q1 25
-144.1%
-10.0%
Q4 24
-133.5%
-0.2%
Q3 24
-653.1%
-42.8%
Q2 24
-2086.9%
-21.3%
Q1 24
-35.0%
EPS (diluted)
IVVD
IVVD
OPRX
OPRX
Q4 25
$0.02
$0.27
Q3 25
$-0.06
$0.04
Q2 25
$-0.12
$0.08
Q1 25
$-0.14
$-0.12
Q4 24
$-0.14
$0.00
Q3 24
$-0.51
$-0.50
Q2 24
$-0.40
$-0.22
Q1 24
$-0.38
$-0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVVD
IVVD
OPRX
OPRX
Cash + ST InvestmentsLiquidity on hand
$226.7M
$23.4M
Total DebtLower is stronger
$26.3M
Stockholders' EquityBook value
$241.5M
$128.3M
Total Assets
$276.9M
$176.9M
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVVD
IVVD
OPRX
OPRX
Q4 25
$226.7M
$23.4M
Q3 25
$85.0M
$19.5M
Q2 25
$34.9M
$16.6M
Q1 25
$48.1M
$16.6M
Q4 24
$69.3M
$13.4M
Q3 24
$106.9M
$16.1M
Q2 24
$147.9M
Q1 24
$189.4M
Total Debt
IVVD
IVVD
OPRX
OPRX
Q4 25
$26.3M
Q3 25
$28.8M
Q2 25
$29.3M
Q1 25
$33.8M
Q4 24
$34.3M
Q3 24
$36.8M
Q2 24
$37.3M
Q1 24
$37.8M
Stockholders' Equity
IVVD
IVVD
OPRX
OPRX
Q4 25
$241.5M
$128.3M
Q3 25
$93.1M
$122.3M
Q2 25
$42.8M
$119.3M
Q1 25
$54.1M
$116.3M
Q4 24
$67.5M
$117.0M
Q3 24
$83.2M
$114.5M
Q2 24
$140.6M
$121.0M
Q1 24
$178.5M
$122.5M
Total Assets
IVVD
IVVD
OPRX
OPRX
Q4 25
$276.9M
$176.9M
Q3 25
$139.2M
$170.3M
Q2 25
$89.1M
$169.3M
Q1 25
$103.7M
$167.8M
Q4 24
$129.5M
$171.2M
Q3 24
$161.9M
$165.2M
Q2 24
$177.3M
$172.9M
Q1 24
$215.5M
$176.4M
Debt / Equity
IVVD
IVVD
OPRX
OPRX
Q4 25
0.20×
Q3 25
0.24×
Q2 25
0.25×
Q1 25
0.29×
Q4 24
0.29×
Q3 24
0.32×
Q2 24
0.31×
Q1 24
0.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVVD
IVVD
OPRX
OPRX
Operating Cash FlowLast quarter
$-15.5M
$7.1M
Free Cash FlowOCF − Capex
$7.1M
FCF MarginFCF / Revenue
22.0%
Capex IntensityCapex / Revenue
0.0%
0.0%
Cash ConversionOCF / Net Profit
1.41×
TTM Free Cash FlowTrailing 4 quarters
$18.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVVD
IVVD
OPRX
OPRX
Q4 25
$-15.5M
$7.1M
Q3 25
$-8.3M
$3.2M
Q2 25
$-13.3M
$4.6M
Q1 25
$-21.1M
$3.9M
Q4 24
$-37.6M
$198.0K
Q3 24
$-41.1M
$1.8M
Q2 24
$-41.6M
$782.0K
Q1 24
$-50.2M
$2.1M
Free Cash Flow
IVVD
IVVD
OPRX
OPRX
Q4 25
$7.1M
Q3 25
$3.2M
Q2 25
$-13.3M
$4.6M
Q1 25
$-21.3M
$3.8M
Q4 24
$-37.6M
$181.0K
Q3 24
$-41.1M
$1.8M
Q2 24
$737.0K
Q1 24
$-50.4M
$2.1M
FCF Margin
IVVD
IVVD
OPRX
OPRX
Q4 25
22.0%
Q3 25
12.2%
Q2 25
-112.9%
15.6%
Q1 25
-188.2%
17.5%
Q4 24
-272.2%
0.6%
Q3 24
-441.6%
8.3%
Q2 24
3.9%
Q1 24
10.6%
Capex Intensity
IVVD
IVVD
OPRX
OPRX
Q4 25
0.0%
0.0%
Q3 25
0.0%
0.0%
Q2 25
0.1%
0.0%
Q1 25
1.3%
0.1%
Q4 24
0.0%
0.1%
Q3 24
0.1%
0.1%
Q2 24
0.0%
0.2%
Q1 24
0.2%
Cash Conversion
IVVD
IVVD
OPRX
OPRX
Q4 25
1.41×
Q3 25
4.11×
Q2 25
2.98×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons